People with MS (Multiple Sclerosis) and others suffering with a range of often debilitating inflammatory conditions such as Chronic Fatigue Syndrome and Fibromyalgia, will take heart from advances in treatment for their conditions, and will follow events at The 2nd European LDN Conference with interest.
“Following the success of last year’s inaugural conference, we are returning to Glasgow. There have been a number of important developments in the past year and this year’s conference is set to be a landmark event.”
Taking place in Glasgow on 24th April, 2010 at the Thistle Hotel in Cambridge Street, The 2010 European LDN conference is again organised by Dr Tom Gilhooly of the Essential Health Clinic in Glasgow with support from Linda Elsegood and the LDN Research Trust. According to Dr Gilhooly, “Following the success of last year’s inaugural conference, we are returning to Glasgow. There have been a number of important developments in the past year and this year’s conference is set to be a landmark event.” The conference is sponsored and supported online by BIG ON Glasgow.
LDN – Low Dose Naltrexone – was initially developed as a treatment in the United States in the 1980s. Working with opiate addicted patients, it was realised that in low doses, Naltrexone could actually be used to increase endorphin levels, effective in the treatment of MS. It was first used as a treatment for MS in 1985.
As an MS sufferer, Linda Elsegood spent two years bed-bound until treatment with LDN enabled her to regain the use of her motor skills. She set up the charity LDN Research Trust with the aim of increasing awareness and to raise funds for clinical trials. The LDN Research Trust has a database of over 3,000 people using LDN treatments in the UK.